Hims & Hers Health (NYSE:HIMS) Stock Price Down 6.7% – What’s Next?

Hims & Hers Health, Inc. (NYSE:HIMS) shares were down 6.7% on Friday . The company traded as low as $31.52 and last traded at $30.5440. Approximately 3,703,262 shares changed hands during trading, a decline of 87% from the average session volume of 27,651,109 shares. The stock had previously closed at $32.74.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Jefferies Financial Group set a $24.50 price target on shares of Hims & Hers Health in a research note on Tuesday, May 12th. Needham & Company LLC lifted their target price on shares of Hims & Hers Health from $30.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. Canaccord Genuity Group boosted their target price on Hims & Hers Health from $32.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. Truist Financial boosted their target price on Hims & Hers Health from $18.00 to $23.00 and gave the company a “hold” rating in a research report on Friday, May 22nd. Finally, Barclays upped their price target on Hims & Hers Health from $29.00 to $39.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 17th. Four research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $31.17.

Hims & Hers Health Price Performance

The company’s 50-day moving average price is $30.69 and its 200-day moving average price is $26.33. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of 2.18. The firm has a market cap of $6.76 billion, a price-to-earnings ratio of -327.00, a PEG ratio of 89.16 and a beta of 2.35.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The business had revenue of $608.10 million during the quarter, compared to analyst estimates of $616.84 million. During the same quarter last year, the firm posted $0.20 EPS. The company’s revenue for the quarter was up 3.8% on a year-over-year basis. On average, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.03 EPS for the current year.

Insider Buying and Selling

In other news, insider Irene Becklund sold 7,573 shares of the company’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $30.25, for a total transaction of $229,083.25. Following the sale, the insider owned 11,280 shares of the company’s stock, valued at approximately $341,220. This represents a 40.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Patrick Harrison Carroll sold 23,726 shares of the stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $35.00, for a total value of $830,410.00. Following the completion of the sale, the insider owned 181,861 shares in the company, valued at approximately $6,365,135. The trade was a 11.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 83,126 shares of company stock worth $2,711,339 over the last three months. 11.76% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. MassMutual Private Wealth & Trust FSB increased its holdings in Hims & Hers Health by 70.0% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock worth $27,000 after purchasing an additional 319 shares during the period. Sigma Planning Corp grew its position in shares of Hims & Hers Health by 1.5% during the first quarter. Sigma Planning Corp now owns 26,007 shares of the company’s stock worth $540,000 after buying an additional 388 shares in the last quarter. BAM Wealth Management LLC grew its position in shares of Hims & Hers Health by 5.6% during the fourth quarter. BAM Wealth Management LLC now owns 7,380 shares of the company’s stock worth $240,000 after buying an additional 393 shares in the last quarter. Captrust Financial Advisors increased its stake in shares of Hims & Hers Health by 3.1% during the second quarter. Captrust Financial Advisors now owns 14,612 shares of the company’s stock worth $728,000 after buying an additional 443 shares during the period. Finally, Binnacle Investments Inc purchased a new stake in shares of Hims & Hers Health during the third quarter worth approximately $28,000. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.